

## Array BioPharma

[View the current Array BioPharma Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/959-Array+BioPharma.html)

(<http://www.bioportfolio.com/bi corporate/959-Array+BioPharma.html>)

### Contact Details:

3200 Walnut Street  
Boulder

Tel: 303-386-1112

Fax: 303-381-6697

Email: [IR@arraybiopharma.com](mailto:IR@arraybiopharma.com).

80301

United States of America

Array BioPharma is a drug discovery company inventing new small molecule drugs through the integration of chemistry, biology and informatics. Our experienced scientists use the Array Discovery Platform, our integrated set of drug discovery technologies, to invent novel small molecule drugs in collaboration with leading pharmaceutical and biotechnology companies and to build our own pipeline of proprietary drug candidates.

### Recent Publications by Array BioPharma:



- [Selective synthesis of 1-functionalized-alkyl-1H-indazoles.](#)  
*An efficient method for the selective "N1" alkylation of indazoles is...*30th October, 2009  
Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301, USA.- *Org Lett.* 2009 Nov 5;11(21):5054-7. ([DOI Direct Link](#))
- [Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition.](#)  
*Gemfibrozil-1-O-beta-glucuronide (GEM-1-O-gluc), a major metabolite of the...*14th October, 2009  
Department of Drug Metabolism, Array Biopharma Inc., 3200 Walnut Street,- *Chem Res Toxicol.* 2009 Jul;22(7):1298-309. ([DOI Direct Link](#))
- [Potent and selective pyrazole-based inhibitors of B-Raf kinase.](#)  
*Herein we describe a novel pyrazole-based class of ATP competitive B-Raf...*17th December, 2008  
Lead Optimization, Array BioPharma, 3200 Walnut Street, Boulder, CO 80301,- *Bioorg Med Chem Lett.* 2008 Aug 15;18(16):4692-5. Epub 2008 Jul 5. ([DOI Direct Link](#))
- [Liquid chromatography-tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E\(2\) in human urine.](#)  
*A LC-MS/MS method has been developed to analyze tetranor PGE-M, the major...*7th October, 2008

Department of Drug Metabolism, Array BioPharma Inc, Boulder, CO 80301,- J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Aug 1;871(1):72-7. ([DOI Direct Link](#))

- [Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors.](#)  
*Tumor cells extensively utilize the pentose phosphate pathway for the...*10th June, 2008  
Array BioPharma Inc., 3200 Walnut Street, Boulder, CO 80301, USA.- Bioorg Med Chem Lett. 2008 Mar 15;18(6):2206-10. Epub 2007 Dec 3. ([DOI Direct Link](#))
- [Non-charged thiamine analogs as inhibitors of enzyme transketolase.](#)  
*Inhibition of the thiamine-utilizing enzyme transketolase (TK) has been...*28th May, 2008  
Array BioPharma Inc., 3200 Walnut Street, Boulder, CO 80301, USA.- Bioorg Med Chem Lett. 2008 Jan 15;18(2):509-12. Epub 2007 Dec 3. ([DOI Direct Link](#))
- [Prodrug thiamine analogs as inhibitors of the enzyme transketolase.](#)  
*Transketolase, a key enzyme in the pentose phosphate pathway, has been...*28th May, 2008  
Array BioPharma Inc., 3200 Walnut Street, Boulder, CO 80301, USA.- Bioorg Med Chem Lett. 2008 Jan 15;18(2):505-8. Epub 2007 Dec 3. ([DOI Direct Link](#))
- [Diversification of the three-component coupling of 2-aminoheterocycles, aldehydes, and isonitriles: efficient parallel synthesis of a diverse and druglike library of imidazo- and tetrahydroimidazo\[1,2-a\] heterocycles.](#)  
*Due to their diverse range of biological activities, imidazoheterocycles...*27th February, 2008  
Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301, USA.- J Comb Chem. 2007 Nov-Dec;9(6):1177-87. Epub 2007 Sep 8. ([DOI Direct Link](#))
- [Improving the performance of self-organizing maps via growing representations.](#)  
*Self-organizing maps (SOMs) are a type of artificial neural network that...*7th November, 2007  
Computational Research, Array BioPharma, Inc, 3200 Walnut Street, Boulder,- J Chem Inf Model. 2007 Sep-Oct;47(5):1797-807. Epub 2007 Aug 18. ([DOI Direct Link](#))
- [The peptidoglycan recognition proteins LCa and LCx.](#)  
*Infection of bacteria triggers innate immune defense reactions in...*7th August, 2007  
Array Biopharma Inc, Boulder, CO 80301, USA.- Cell Mol Life Sci. 2007 Jun;64(11):1395-402. ([DOI Direct Link](#))
- [Tetrazole and ester substituted tetrahydroquinoxalines as potent cholesteryl ester transfer protein inhibitors.](#)  
*Cholesteryl ester transfer protein is a plasma glycoprotein that transfers...*25th July, 2007  
Array BioPharma, 3200 Walnut Street Boulder, CO 80301, USA.- Bioorg Med Chem Lett. 2007 May 1;17(9):2608-13. Epub 2007 Feb 8. ([DOI Direct Link](#))
- [Biological characterization of ARRY-142886 \(AZD6244\), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.](#)  
*PURPOSE: The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway...*10th May, 2007  
Array BioPharma, Inc., Boulder, Colorado 80301, USA.- Clin Cancer Res. 2007 Mar 1;13(5):1576-83. ([DOI Direct Link](#))
- [Preparation of pyrrolidine-based PDE4 inhibitors via enantioselective conjugate addition of alpha-substituted malonates to aromatic nitroalkenes.](#)  
*[reaction: see text] The enantioselective conjugate addition of...*22nd December, 2006  
Department of Process Chemistry Research, Array BioPharma, 3200 Walnut- Org Lett. 2006 Mar 30;8(7):1495-8. ([DOI Direct Link](#))
- [Development of new cancer therapeutic agents targeting mitosis.](#)  
*Targeting cellular proliferation persists as a mainstay of cancer...*20th October, 2006  
Array BioPharma, Inc., 3200 Walnut Street, Boulder, CO 80301, USA.- Expert Opin Investig Drugs. 2006 Nov;15(11):1411-25. ([DOI Direct Link](#))
- [Identification and evaluation of molecular properties related to preclinical optimization and clinical fate.](#)  
*The economic case for fundamental changes that are required to ensure long...*25th July, 2006  
Array BioPharma, Inc., 3200 Walnut Street, Boulder, CO 80301, USA.- Med Chem. 2005 Nov;1(6):649-55.

## Press Releases on Array BioPharma:

|  |                     |                                     |   |
|--|---------------------|-------------------------------------|---|
| <a href="#">PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend</a>   | 23rd November, 2009 | PDL BioPharma, Inc.                 | INCLINE VILLAGE, Nev., Nov. 23 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that NASDAQ has established November 27, 2009 as the ex-dividend date for its \$200 |
| <a href="#">Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update</a> | 23rd November, 2009 | Wound Management Technologies, Inc. | FORT WORTH, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced that it has  |
| <a href="#">Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines</a>                             | 20th November, 2009 | Soligenix, Inc.                     | PRINCETON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company,  |
| <a href="#">Soligenix Reports Third Quarter 2009 Financial Results</a>   | 13th November, 2009 | Soligenix, Inc.                     | -- The granting of Orphan Drug Designation by the FDA's Office of Orphan Products Development for oral BDP (beclomethasone 17,21-dipropionate, or orBec®) for the treatment                           |
| <a href="#">PDL BioPharma Announces Special Dividend Payment</a>   | 12th November, 2009 | PDL BioPharma, Inc.                 | INCLINE VILLAGE, Nev., Nov. 12 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it will pay a \$200 million special dividend to stockholders, with part of the |

## BioNews Results for Array BioPharma



- [Horizon Discovery to Collaborate with Novartis](#)  
GenomeWeb: Nov 21 2009 4:49AM Matching: array biopharma
- [Array Biopharma Down 31% Since SmarTrend's Sell Recommendation](#)

- TradingMarkets: Nov 19 2009 7:49PM Matching: array biopharma
- [Array BioPharma Down 29.2% Since SmarTrend's Sell Recommendation ...](#)  
Zibb: Nov 13 2009 5:50AM Matching: array biopharma
  - [Array BioPharma Down 29.2% Since SmarTrend's Sell Recommendation](#)  
Individual.com: Nov 13 2009 5:18AM Matching: array biopharma
  - [UBS Upgrades Array BioPharma \(ARRY\) to Buy](#)  
Street Insider: Nov 5 2009 2:18PM Matching: array biopharma
  - [Array BioPharma Releases Financial Results for the 1Q of Fiscal 2010](#)  
Individual.com: Nov 5 2009 11:07AM Matching: array biopharma
  - [Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2010](#)  
Pharma Live: Nov 3 2009 2:10AM Matching: array biopharma
  - [Array BioPharma Inc. F1Q10 \(Quarter Ended June 30, 2010\) Earnings Call Transcript](#)  
Seeking Alpha: Nov 3 2009 4:59PM Matching: array biopharma
  - [Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2010](#)  
Individual.com: Nov 3 2009 12:28AM Matching: array biopharma
  - [Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2010](#)  
Individual.com: Nov 3 2009 12:20AM Matching: array biopharma
  - [Array BioPharma, of Boulder, posts higher revenue for its fiscal 1Q](#)  
Individual.com: Nov 3 2009 2:12AM Matching: array biopharma
  - [Array BioPharma Schedules 1Q 2010 Financial Results Release and C...](#)  
Zibb: Nov 2 2009 7:41AM Matching: array biopharma
  - [Array BioPharma Reports Financial Results for the First Quarter](#)  
Business Wire via MSN Money: Nov 2 2009 9:45PM Matching: array biopharma
  - [Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2010](#)  
Genetic Engineering News: Nov 2 2009 10:25PM Matching: array biopharma
  - [Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2010](#)  
Street Insider: Nov 2 2009 9:50PM Matching: array biopharma

#### Array BioPharma Clinical Trials:



- [Tolerability Study of Investigational Agent, ARRY-334543, in Patients With Cancer](#)

#### Array BioPharma Patents:



- 7598383- [Heterocyclic inhibitors of MEK and methods of use thereof](#)
- 7271178- [Heterocyclic inhibitors of MEK and methods of use thereof](#)
- 7235537- [N3 alkylated benzimidazole derivatives as MEK inhibitors](#)

- 7230099- [Heterocyclic inhibitors of MEK and methods of use thereof](#)
- 7226906- [Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases](#)
- 7199244- [Cyclic amine derivatives and methods of use](#)
- 7169926- [Dipeptidyl peptidase inhibitors](#)
- 7144988- [Method of structure-based drug design to create or improve modulators of IL-1 activity which bind to the interleukin-1 type 1 receptor](#)
- 7144907- [Heterocyclic inhibitors of MEK and methods of use thereof](#)
- 7135575- [P38 inhibitors and methods of use thereof](#)
- 7078425- [Preparation of phosphatase inhibitors](#)
- 6911554- [Isocyano substituted polystyrene carbonate resin for use in 3 and 4 component condensation reactions](#)
- 6586467- [Preparation of phosphatase inhibitors](#)
- 6462238- [Process for the reduction of cyano-substituted sulfones to aminoalkylene-substituted sulfones](#)
- 6403379- [Reactor plate washing station](#)
- 6379626- [Reactor plate clamping system](#)
- 6362216- [Compounds which inhibit tryptase activity](#)
- 7294616- [Capreomycin derivatives and their use as antibacterials](#)
- 7425631- [Compounds and methods of use](#)
- 7585975- [Quinazoline analogs as receptor tyrosine kinase inhibitors](#)
- 7576114- [N3 alkylated benzimidazole derivatives as MEK inhibitors](#)
- 7576072- [Heterocyclic inhibitors of MEK and methods of use thereof](#)
- 7566716- [Imidazopyrazines as Raf inhibitor compounds](#)
- 7553842- [Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases](#)
- 7538120- [Method of treating inflammatory diseases](#)
- 7521447- [P38 inhibitors and methods of use thereof](#)
- 7517994- [Heterocyclic inhibitors of MEK and methods of use thereof](#)
- 7511058- [Heterocyclic inhibitors of MEK and methods of use thereof](#)
- 7501427- [Quinazoline analogs as receptor tyrosine kinase inhibitors](#)
- 7491829- [RAF inhibitor compounds and methods](#)
- 7488823- [Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors](#)
- 7485643- [Bicyclic inhibitors of MEK and methods of use thereof](#)
- 7452895- [Quinazoline analogs as receptor tyrosine kinase inhibitors](#)
- 7449486- [Mitotic kinesin inhibitors and methods of use thereof](#)
- 7425637- [N3 alkylated benzimidazole derivatives as MEK inhibitors](#)
- 6221914- [Sulfonamide bridging compounds that inhibit tryptase activity](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo

- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

